• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Analyst Comment

Zerion Pharma: A disruptive solution for poor drug solubility

By HC Andersen Capital
Zerion Pharma

CEO Ole Wiborg dived into the potential in the pipeline and where focus will be in the medium to long term. The company decided to change the offering in the private placement.

Watch the video here: https://www.inderes.dk/en/videos/zerion-pharma-a-disruptive-solution-for-poor-drug-solubility.

Zerion Pharma is a non-listed Danish company seeking DKK 5-8 mio. in a private placement round.

Closing date 20. April 2023, Lot size DKK 250.000 and pre-money valuation DKK 70 mio.

Contact: CEO Ole Wiborg - ow@zerion.eu or CFO Jakob Dynnes Hansen - jdh@zerion.eu if you are interested to subscribe and further details.

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a DigitalIR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Analyst Claus Thestrup/ANALYST Claus Thestrup 5:30/PM 03-16-2023.